Get the Daily Brief
Latest Biotech News
Frazier Closes $1.3 Billion Fund to Fuel Early-Stage Biotech
Life sciences venture firm Frazier Life Sciences announced the closing of a $1.3 billion early-stage fund to support startup creation and investing in innovative biotech companies. The fund aims...
Novel AI Tool Illuminates Hidden Microproteins in the Genome
Researchers at the Salk Institute developed ShortStop, an artificial intelligence framework designed to identify microproteins encoded in genomic regions previously considered noncoding 'dark...
Breakthroughs in Cancer Metabolism and Immune Modulation
Recent advances have elucidated novel mechanisms in cancer biology. One study demonstrated that breast cancer cells can hijack mitochondria from neurons to fuel metastasis, revealing a new...
Advances in AI and Machine Learning Transforming Diagnostics
Cutting-edge artificial intelligence technologies continue to reshape medical diagnostics. A new multimodal deep learning framework enhances explainability in predicting thyroid cancer metastasis...
Clinical and Regulatory Updates: FDA Actions and New Approvals
The FDA continues to issue critical regulatory decisions impacting biotech pipelines. Notably, Lenz Therapeutics received U.S. approval for its aceclidine-based eye drop for presbyopia, marking a...
Trump Demands Pharma Align US Drug Prices with Global Levels
President Donald Trump intensified efforts to lower drug prices in the US by issuing letters to 17 major pharmaceutical companies, demanding compliance with a 'most favored nation' pricing plan...
Alnylam's Amvuttra Surges on Rare Heart Disease Launch
Alnylam Pharmaceuticals reported a robust second-quarter performance driven by its rare heart disease drug Amvuttra, whose sales more than doubled year over year to $492 million. The product's...
Moderna Plans 10% Workforce Reduction Amid Cost-Cutting
Moderna announced plans to reduce its global workforce by approximately 10%, representing over 800 employees, as part of a broader effort to cut $1.5 billion in annual operating expenses by 2027....
Frazier Life Sciences Raises $1.3 Billion for Early-Stage Biotech
Veteran venture capital firm Frazier Life Sciences closed a $1.3 billion fund aimed at supporting startup creation and investing in early-stage biotechnology companies. This represents one of the...
New AI Tool Reveals Hidden Microproteins in Genome
Researchers at the Salk Institute developed ShortStop, a machine learning platform designed to identify microproteins coded by previously overlooked noncoding regions of the genome. By mining...
Regeneron's Regulatory Setbacks Temper Strong Q2 Results
Regeneron Pharmaceuticals reported solid second-quarter earnings surpassing expectations, yet faced multiple regulatory challenges. The FDA issued complete response letters delaying approvals of...
Cancer Metabolism Insights Reveal New Treatment Approaches
Recent studies illuminate how cancer cells manipulate metabolic pathways and the tumor microenvironment to facilitate progression and therapy resistance. Findings include breast cancer cells...
AI Advances Accelerate Diagnostics and Therapeutic Developments
Artificial intelligence continues to reshape biotechnology, enabling faster and more accurate diagnostics, personalized therapeutics, and innovative drug discovery. Breakthroughs include a new AI...
Biopharma Financing and Market Trends in 2025
Despite broader market challenges including regulatory uncertainty and reduced scientific funding, significant capital continues to flow into biopharma companies. Funding highlights include large...
Moderna’s UK Patent Victory Enhances mRNA Vaccine Edge
Moderna won a significant patent battle in the UK Appeals Court, confirming the validity of its patent on a modified mRNA technology used in COVID-19 vaccines. The ruling upholds a previous...
Frazier Life Sciences Secures $1.3 Billion for Early-Stage Biotech Ventures
Venture capital firm Frazier Life Sciences announced the closing of a $1.3 billion fund focused on early-stage biotechnology company creation and investments. The fund, one of the largest raised...
Alnylam’s Amvuttra Launch Surpasses Expectations with Rapid Uptake
Alnylam Pharmaceuticals reported an outstanding second-quarter performance driven by its rare disease drug Amvuttra, with sales more than doubling year over year to $492 million. The drug’s uptake...
Regeneron Faces Regulatory Delays Amid Strong Financial Results
Regeneron Pharmaceuticals announced robust second-quarter earnings with revenues surpassing forecasts by 11% and significant earnings per share gains. However, three high-dose Eylea drug...
AI Tools and Advances Illuminate Hidden Layers of the Human Genome
Researchers at the Salk Institute developed ShortStop, an advanced machine learning framework to identify elusive microproteins encoded by rarely studied regions of the genome, challenging the...
Breakthroughs in Gene and Cell Therapy Targeting Cardiovascular and Neurological Disorders
Innovative gene and cell therapy approaches are gaining momentum for hard-to-treat diseases. Lexeo Therapeutics and Tenaya Therapeutics pursue AAV-based gene therapies targeting inherited...